Mycoses

Possible Microbial Contamination Prompts Voluntary Recall of Diabetes Drug

Possible Microbial Contamination Prompts Voluntary Recall of Diabetes Drug

By

FDA posts a notification for a voluntarily recall of a diabetes drug over microbial contamination.

Long-Term Outcomes Following Prosthetic Valve Endocarditis Caused by <i>Candida</i>

Long-Term Outcomes Following Prosthetic Valve Endocarditis Caused by Candida

By

Six-month survival was better in patients who received liposomal amphotericin B-based monotherapy than in those receiving a candin-based monotherapy.

Novel Antifungal Agent for Treatment of <i>Aspergillus flavus</i> Infections

Novel Antifungal Agent for Treatment of Aspergillus flavus Infections

By

F901318 has potent in vitro activity against A flavus and is highly active in both in vitro and in vivo models mimicking invasive human disease.

The T2Candida Panel Has Decreased Time to Therapy Initiation for Candidemia

The T2Candida Panel Has Decreased Time to Therapy Initiation for Candidemia

By

Antimicrobial stewardship traditionally focuses on optimal use of antibacterial agents, not antifungal therapy.

T2 Candida Panel is Superior to Blood Cultures for Identifying Candidemia

T2 Candida Panel is Superior to Blood Cultures for Identifying Candidemia

By

Compared to blood cultures, T2 Candida Panel is faster and more sensitive in detecting Candidemia.

<i>Candida auris</i>: Dispatch From an Outbreak

Candida auris: Dispatch From an Outbreak

By

Rapid identification of Candida auris is crucial in order to implement appropriate precautions and avoid transmission to other patients.

Aspergillosis, An Emerging Complication of Severe Flu Infections

Aspergillosis, An Emerging Complication of Severe Flu Infections

By

Drs Tapper and Crum-Cianflone discuss aspergillosis, an emerging complication of severe influenza infections.

TNF Inhibitors and Risk Factors for Fungal and Mycobacterial Infections

TNF Inhibitors and Risk Factors for Fungal and Mycobacterial Infections

Researchers designed a case-control study using de-identified commercial health claim information in the United States from January 1, 2007, to December 31, 2009.

Sign Up for Free e-newsletters